Scarica l'app Stockscreener
93.64
1.24%
-1.18
Dopo l'orario di chiusura:
93.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$94.82
Aprire:
$94.43
Volume 24 ore:
3.66M
Relative Volume:
0.72
Capitalizzazione di mercato:
$53.92B
Reddito:
$6.30B
Utile/perdita netta:
$1.07B
Rapporto P/E:
50.87
EPS:
1.8406
Flusso di cassa netto:
$1.09B
1 W Prestazione:
+1.79%
1M Prestazione:
+9.07%
6M Prestazione:
+10.71%
1 anno Prestazione:
+22.58%
Intervallo 1D:
$92.89
$95.13
Intervallo di 1 settimana:
$91.82
$96.29
Portata 52W:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
93.64 | 54.60B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
95.18 | 166.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
326.85 | 126.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
82.01 | 107.31B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.81 | 67.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Edwards Lifesciences (NYSE:EW) Valve Data Keeps Healthcare Focus - Kalkine Media
Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid - AD HOC NEWS
The Edwards SAPIEN 3 Ultra ValvePrecision Transcatheter Option For US Heart Patients - AD HOC NEWS
Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com - Investing.com Nigeria
Edwards Lifesciences’ SWOT analysis: stock gains momentum on market share opportunity - Investing.com
Edwards Lifesciences (EW) executive has shares withheld for tax on vesting - Stock Titan
Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth prosp - AD HOC NEWS
Edwards Lifesciences Investors Seek 1st OK For $39M Deal - Law360
EWEdwards Lifesciences Corp Latest SEC Filings - Finviz
EW Maintained by Evercore ISI Group -- Price Target Raised to $1 - GuruFocus
Edwards Lifesciences Corp (EW): Analyst Consensus Points to Growth Potential in the Medical Device Sector - DirectorsTalk Interviews
Edwards Lifesciences stock leans on its core heart valve business - AD HOC NEWS
Law firm investigates Edwards Lifesciences offi... - Pluang
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders? - marketscreener.com
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick By Investing.com - Investing.com Nigeria
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick - Investing.com
Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com - Investing.com Nigeria
Edwards Lifesciences stock hits 52-week high at 92.94 USD - Investing.com
Top Edwards Lifesciences (EW) Competitors 2026 - MarketBeat
What You Need To Know Ahead of Edwards Lifesciences' Earnings Release - Yahoo Finance
Edwards Lifesciences highlights heart valve portfolio as investors watch long-term growth - AD HOC NEWS
Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com - Investing.com Nigeria
Form 4 Edwards Lifesciences Corp For: 30 June By Investing.com - Investing.com Canada
TAX MANAGED MULTI CAP GROWTH PORTFOLIO's Edwards Lifesciences Corp(EW) Holding History - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock - Investing.com
Edwards Lifesciences (NYSE: EW) exec sells 619 shares under 10b5-1 plan - Stock Titan
BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences (EW) Gains FDA Approval for Ecliptis System - GuruFocus
Edwards Lifesciences Corporation(NYSE: EW) added to Russell Midcap Value Benchmark - marketscreener.com
Edwards Lifesciences: The Heart of OC Medtech - Orange County Business Journal
Edwards Lifesciences presents fresh trial data, shares supported by robust S&P 500 positioning - AD HOC NEWS
Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN - MarketBeat
Edwards Lifesciences Reports New Clinical Trial Updates - Orange County Business Journal
Edwards Lifesciences presents trial data at New York conference - Investing.com
Edwards Lifesciences presents trial data at New York conference By Investing.com - Investing.com UK
Edwards brings fresh valve data to New York, with TAVR study update - Stock Titan
A Look at Edwards Lifesciences Corp (EW) After 3.1% Gain -- GF V - GuruFocus
Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com - Investing.com South Africa
Edwards Lifesciences stock hits 52-week high at 89.7 USD - Investing.com
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences clears fresh Medicare hurdle, shares consolidate after 52-week high - Ad-hoc-news.de
Edwards Lifesciences Corp (EW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAPIEN 3 Ultra from Edwards Lifesciences Corp.lower-profile TAVI and refined delivery - AD HOC NEWS
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch
Edwards Lifesciences Stocklong-term heart valve strategy in focus - AD HOC NEWS
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):